Business Description
Kura Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US50127T1097
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.38 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7 | |||||
| 3-Year EPS without NRI Growth Rate | -7.2 | |||||
| 3-Year FCF Growth Rate | -7.9 | |||||
| 3-Year Book Growth Rate | -16.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -5.86 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.83 | |||||
| 9-Day RSI | 17.21 | |||||
| 14-Day RSI | 20.74 | |||||
| 6-1 Month Momentum % | -16.02 | |||||
| 12-1 Month Momentum % | 87.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.47 | |||||
| Quick Ratio | 11.47 | |||||
| Cash Ratio | 11.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -17.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -44.45 | |||||
| ROA % | -39.98 | |||||
| ROIC % | -791.87 | |||||
| ROC (Joel Greenblatt) % | -2336.26 | |||||
| ROCE % | -42.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 2.05 | |||||
| EV-to-EBIT | -2.19 | |||||
| EV-to-Forward-EBIT | -1.68 | |||||
| EV-to-EBITDA | -2.2 | |||||
| EV-to-Forward-EBITDA | -1.68 | |||||
| EV-to-Forward-Revenue | 16.52 | |||||
| EV-to-FCF | -2.54 | |||||
| Price-to-Net-Current-Asset-Value | 2.13 | |||||
| Price-to-Net-Cash | 2.17 | |||||
| Earnings Yield (Greenblatt) % | -45.66 | |||||
| FCF Yield % | -19.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kura Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.163 | ||
| Beta | 0.2 | ||
| Volatility % | 67.47 | ||
| 14-Day RSI | 20.74 | ||
| 14-Day ATR (€) | 0.595964 | ||
| 20-Day SMA (€) | 14.50435 | ||
| 12-1 Month Momentum % | 87.51 | ||
| 52-Week Range (€) | 8.5 - 21.4 | ||
| Shares Outstanding (Mil) | 77.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kura Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kura Oncology Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kura Oncology Inc Frequently Asked Questions
What is Kura Oncology Inc(FRA:KUR)'s stock price today?
The current price of FRA:KUR is €10.00. The 52 week high of FRA:KUR is €21.40 and 52 week low is €8.50.
When is next earnings date of Kura Oncology Inc(FRA:KUR)?
The next earnings date of Kura Oncology Inc(FRA:KUR) is 2025-02-27 Est..
Does Kura Oncology Inc(FRA:KUR) pay dividends? If so, how much?
Kura Oncology Inc(FRA:KUR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers